While other studies showed that no benefit was observed for adjuvant chemotherapy in very small tumors, such as T1mi, T1a, and T1b HER2-positive or triple-negative breast cancers with no axillary metastasis (31, 32). Here, ERBB2 is linked to triple-negative breast carcinoma.